California Public Employees Retirement System Krystal Biotech, Inc. Transaction History

California Public Employees Retirement System

$135 Billion
Q2 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$62.14 - $81.82 $1.71 Million - $2.25 Million	-27,500 Closed	0 $0
Q4 2020 Feb 02, 2021	SELL	$40.64 - $61.38 $53,157 - $80,285	-1,308 Reduced 4.54%	27,500 $1.65 Million
Q3 2020 Nov 05, 2020	BUY	$37.76 - $48.49 $61,926 - $79,523	1,640 Added 6.04%	28,808 $1.24 Million
Q2 2020 Aug 12, 2020	BUY	$37.03 - $60.0 $140,306 - $227,340	3,789 Added 16.21%	27,168 $1.13 Million
Q1 2020 May 12, 2020	SELL	$35.02 - $65.64 $1.17 Million - $2.2 Million	-33,509 Reduced 58.9%	23,379 $1.01 Million
Q4 2019 Jan 27, 2020	BUY	$33.17 - $65.23 $1.44 Million - $2.83 Million	43,409 Added 322.05%	56,888 $3.15 Million
Q3 2019 Oct 31, 2019	BUY	$34.72 - $51.3 $70,759 - $104,549	2,038 Added 17.81%	13,479 $468,000
Q2 2019 Aug 15, 2019	BUY	$27.2 - $41.2 $93,595 - $141,769	3,441 Added 43.01%	11,441 $461,000
Q1 2019 May 03, 2019	BUY	$19.86 - $32.9 $158,880 - $263,200	8,000 New	8,000 $263,000

Others Institutions Holding KRYS

# of Institutions

275

Shares Held

24.9M

Call Options Held

270K

Put Options Held

172K

Black Rock Inc. New York, NY

3.95M
Shares

$698 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

2.87M
Shares

$508 Million
0.01% of portfolio
Avoro Capital Advisors LLC New York, NY

2.43M
Shares

$430 Million
6.1% of portfolio
State Street Corp Boston, MA

1.33M
Shares

$236 Million
0.01% of portfolio
Redmile Group, LLC San Francisco, CA

1.02M
Shares

$181 Million
12.22% of portfolio

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.54B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account